Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects with any stable disease that are at risk for a venous or arterial thrombotic
disorder

- Neonates up to 28 days of age (>= 34 weeks gestational age or >= 37 weeks post
conceptual age) to <18 years of age

- Subjects with any functional CVAD (Central Venous Access Device) in the upper or lower
venous system

Exclusion Criteria:

- Current or recent (within 3 months of study drug administration) gastrointestinal
disease or gastrointestinal surgery that, in the opinion of the investigator and the
BMS Medical Monitor, could impact the absorption of the study drug

- Active bleeding or high risk of bleeding

- Inability to tolerate oral medication or administration of oral medication via an
enteral tube (nasogastric tube [NG tube] or gastronomy tube [G-tube])